Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 82
Filter
1.
J Hosp Infect ; 139: 23-32, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37308063

ABSTRACT

BACKGROUND: The COG-UK hospital-onset COVID-19 infection (HOCI) trial evaluated the impact of SARS-CoV-2 whole-genome sequencing (WGS) on acute infection, prevention, and control (IPC) investigation of nosocomial transmission within hospitals. AIM: To estimate the cost implications of using the information from the sequencing reporting tool (SRT), used to determine likelihood of nosocomial infection in IPC practice. METHODS: A micro-costing approach for SARS-CoV-2 WGS was conducted. Data on IPC management resource use and costs were collected from interviews with IPC teams from 14 participating sites and used to assign cost estimates for IPC activities as collected in the trial. Activities included IPC-specific actions following a suspicion of healthcare-associated infection (HAI) or outbreak, as well as changes to practice following the return of data via SRT. FINDINGS: The mean per-sample costs of SARS-CoV-2 sequencing were estimated at £77.10 for rapid and £66.94 for longer turnaround phases. Over the three-month interventional phases, the total management costs of IPC-defined HAIs and outbreak events across the sites were estimated at £225,070 and £416,447, respectively. The main cost drivers were bed-days lost due to ward closures because of outbreaks, followed by outbreak meetings and bed-days lost due to cohorting contacts. Actioning SRTs, the cost of HAIs increased by £5,178 due to unidentified cases and the cost of outbreaks decreased by £11,246 as SRTs excluded hospital outbreaks. CONCLUSION: Although SARS-CoV-2 WGS adds to the total IPC management cost, additional information provided could balance out the additional cost, depending on identified design improvements and effective deployment.


Subject(s)
COVID-19 , Cross Infection , Humans , SARS-CoV-2/genetics , Cross Infection/epidemiology , Cross Infection/prevention & control , COVID-19/epidemiology , COVID-19/prevention & control , Infection Control , Hospitals
2.
J Infect Public Health ; 15(10): 1118-1123, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36137361

ABSTRACT

BACKGROUND: Nosocomial acquisition of influenza is known to occur but the risk after exposure to a known case and the outcomes after acquisition are poorly defined. METHODS: Prospective observational study of patients exposed to influenza from another patient in a multi-site healthcare organisation, with follow-up of 7 days or until discharge, and PCR-confirmation of symptomatic disease. Multivariable analysis was used to investigate association of influenza acquisition with high dependency unit/intensive care unit (HDU/ITU) admission and in-hospital mortality. RESULTS: 23/298 (7.7%) contacts of 11 cases were subsequently symptomatic and tested influenza-positive during follow-up. HDU/ITU admission was significantly higher in these secondary cases (6/23, 26%) compared to flu-negative contacts (20/275, 7.2%; p = 0.002). In-hospital mortality was significantly higher in secondary cases (5/23, 21.7%) compared to flu-negative contacts (11/275, 4%; p < 0.001). In multivariable analysis, age (OR 1.25 95% CI: 1.01-1.54, p = 0.02) and being a secondary case (OR 4.77, 95% CI: 1.63-13.9, p = 0.008) were significantly associated with HDU/ITU admission in contacts. Age (OR 1.00, 95% CI: 0.93-1.00, p = 0.02), being a secondary case after exposure to influenza (OR 3.81, 95% CI 1.09-13.3, p = 0.049) and co-morbidity (OR 1.29 per unit increment in the Charlson score, 95% CI 1.02-1.61, p = 0.03) were significantly associated with in-hospital mortality in contacts. CONCLUSIONS: Nosocomial acquisition of influenza was significantly associated with increased risk of HDU/ITU admission and in-hospital mortality.


Subject(s)
Cross Infection , Influenza, Human , Humans , Influenza, Human/complications , Influenza, Human/epidemiology , Cross Infection/epidemiology , Hospitalization , Prospective Studies , Intensive Care Units , Morbidity
3.
Infect Prev Pract ; 3(4): 100186, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34812417

ABSTRACT

BACKGROUND: Point-of-care (POC) SARS-CoV-2 lateral-flow antigen detection (LFD) testing in the emergency department (ED) could inform rapid infection control decisions but requirements for safe deployment have not been fully defined. METHODS: Review of LFD test results, laboratory and POC-RT-PCR results and ED-performance metrics during a two-week high SARS-CoV-2 prevalence period followed by several months of falling prevalence. AIM: Determine whether LFD testing can be safely deployed in ED to provide an effective universal SARS-CoV-2 testing capability. FINDINGS: 93% (345/371) of COVID-19 patients left ED with a virological diagnosis during the 2-week universal LFD evaluation period compared to 77% with targeted POC-RT-PCR deployment alone, on background of approximately one-third having an NHS Track and Trace RT-PCR test-result at presentation. LFD sensitivity and specificity was 70.7% and 99.1% respectively providing a PPV of 97.7% and NPV of 86.4% with disease prevalence of 34.7%. ED discharge-delays (breaches) attributable to COVID-19 fell to 33/3532 (0.94%) compared with the preceding POC-RT-PCR period (107/4114 (2.6%); p=<0.0001). Importantly, LFD testing identified 1 or 2 clinically-unsuspected COVID-19 patients/day. Three clinically-confirmed LFD false positive patients were appropriately triaged based on LFD action-card flowchart, and only 5 of 95 false-negative LFD results were inappropriately admitted to non-COVID-19 areas where no onward-transmission was identified. LFD testing was restricted to asymptomatic patients when disease prevalence fell below 5% and detected 1-3 cases/week. CONCLUSION: Universal SARS-CoV-2 LFD testing can be safely and effectively deployed in ED alongside POC-RT-PCR testing during periods of high and low disease prevalence.

4.
Dig Liver Dis ; 53(5): 545-557, 2021 05.
Article in English | MEDLINE | ID: mdl-33775575

ABSTRACT

Acute liver failure (ALF) is a clinical condition characterized by the abrupt onset of coagulopathy and biochemical evidence of hepatocellular injury, leading to rapid deterioration of liver cell function. In children, ALF has been characterized by raised transaminases, coagulopathy, and no known evidence of pre-existing chronic liver disease; unlike in adults, the presence of hepatic encephalopathy is not required to establish the diagnosis. Although rare, ALF has a high mortality rate without liver transplantation (LT). Etiology of ALF varies with age and geographical location, although it may remain indeterminate in a significant proportion of cases. However, identifying its etiology is crucial to undertake disease-specific management and evaluate indication to LT. In this position statement, the Liver Disease Working Group of the Italian Society of Gastroenterology, Hepatology and Nutrition (SIGENP) reviewed the most relevant studies on pediatric ALF to provide recommendations on etiology, clinical features and diagnostic work-up of neonates, infants and children presenting with ALF. Recommendations on medical management and transplant candidacy will be discussed in a following consensus conference.


Subject(s)
Liver Failure, Acute/diagnosis , Acetaminophen/adverse effects , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Italy , Liver Failure, Acute/blood , Liver Failure, Acute/etiology , Liver Failure, Acute/therapy
5.
Philos Trans A Math Phys Eng Sci ; 377(2137)2018 Dec 10.
Article in English | MEDLINE | ID: mdl-30530541

ABSTRACT

A short description of the muon tomography demonstrator at the INFN Laboratori Nazionali di Legnaro near Padua, Italy, is given and the principal achievements owing to the data collected at that experimental facility are presented. In particular, the feasibility studies for several applications based on the muon-tomographic technology, within national and European projects, are discussed. The experimental problems and the procedures used to improve the performance are underlined. In addition, new activities and the related detector optimization are illustrated.This article is part of the Theo Murphy meeting issue 'Cosmic-ray muography'.

6.
Philos Trans A Math Phys Eng Sci ; 376(2116)2018 Mar 28.
Article in English | MEDLINE | ID: mdl-29459413

ABSTRACT

The efficient production of cold antihydrogen atoms in particle traps at CERN's Antiproton Decelerator has opened up the possibility of performing direct measurements of the Earth's gravitational acceleration on purely antimatter bodies. The goal of the AEgIS collaboration is to measure the value of g for antimatter using a pulsed source of cold antihydrogen and a Moiré deflectometer/Talbot-Lau interferometer. The same antihydrogen beam is also very well suited to measuring precisely the ground-state hyperfine splitting of the anti-atom. The antihydrogen formation mechanism chosen by AEgIS is resonant charge exchange between cold antiprotons and Rydberg positronium. A series of technical developments regarding positrons and positronium (Ps formation in a dedicated room-temperature target, spectroscopy of the n=1-3 and n=3-15 transitions in Ps, Ps formation in a target at 10 K inside the 1 T magnetic field of the experiment) as well as antiprotons (high-efficiency trapping of [Formula: see text], radial compression to sub-millimetre radii of mixed [Formula: see text] plasmas in 1 T field, high-efficiency transfer of [Formula: see text] to the antihydrogen production trap using an in-flight launch and recapture procedure) were successfully implemented. Two further critical steps that are germane mainly to charge exchange formation of antihydrogen-cooling of antiprotons and formation of a beam of antihydrogen-are being addressed in parallel. The coming of ELENA will allow, in the very near future, the number of trappable antiprotons to be increased by more than a factor of 50. For the antihydrogen production scheme chosen by AEgIS, this will be reflected in a corresponding increase of produced antihydrogen atoms, leading to a significant reduction of measurement times and providing a path towards high-precision measurements.This article is part of the Theo Murphy meeting issue 'Antiproton physics in the ELENA era'.

7.
Nat Commun ; 5: 4538, 2014 Jul 28.
Article in English | MEDLINE | ID: mdl-25066810

ABSTRACT

The precise measurement of forces is one way to obtain deep insight into the fundamental interactions present in nature. In the context of neutral antimatter, the gravitational interaction is of high interest, potentially revealing new forces that violate the weak equivalence principle. Here we report on a successful extension of a tool from atom optics--the moiré deflectometer--for a measurement of the acceleration of slow antiprotons. The setup consists of two identical transmission gratings and a spatially resolving emulsion detector for antiproton annihilations. Absolute referencing of the observed antimatter pattern with a photon pattern experiencing no deflection allows the direct inference of forces present. The concept is also straightforwardly applicable to antihydrogen measurements as pursued by the AEgIS collaboration. The combination of these very different techniques from high energy and atomic physics opens a very promising route to the direct detection of the gravitational acceleration of neutral antimatter.

8.
Appl Radiat Isot ; 92: 6-11, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24972161

ABSTRACT

A commercial boron-loaded liquid scintillator EJ-339 A was studied, using a (252)Cf source with/without polyethylene moderator, to examine the possibility of discriminating slow-neutron induced events in (10)B from fast-neutron events, resulting from proton recoils, and gamma-ray events. Despite the strong light quenching associated with neutron induced events in (10)B, correct classification of these events is shown to be possible with the aid of digital signal processing.

9.
Appl Radiat Isot ; 89: 79-84, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24607532

ABSTRACT

The light output response and the neutron and gamma-ray detection efficiency are determined for liquid scintillator EJ-309. The light output function is compared to those of previous studies. Experimental efficiency results are compared to predictions from GEANT4, MCNPX and PENELOPE Monte Carlo simulations. The differences associated with the use of different light output functions are discussed.

10.
Appl Radiat Isot ; 73: 52-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23276691

ABSTRACT

A new laboratory facility for non-destructive analysis (NDA) using a time-tagged (252)Cf source is presented. The system is designed to analyze samples having maximum size of about 20 × 25 cm(2), the material recognition being obtained by measuring simultaneously total and energy dependent transmission of neutrons and gamma rays. The equipment technical characteristics and performances of the NDA system are presented, exploring also limits due to the sample thickness. Some recent applications in the field of cultural heritage are presented.

11.
Phys Rev Lett ; 108(17): 172701, 2012 Apr 27.
Article in English | MEDLINE | ID: mdl-22680857

ABSTRACT

Clustering in low density nuclear matter has been investigated using the NIMROD multidetector at Texas A&M University. Thermal coalescence modes were employed to extract densities, ρ, and temperatures, T, for evolving systems formed in collisions of 47A MeV (40)Ar+(112)Sn, (124)Sn and (64)Zn+(112)Sn, (124)Sn. The yields of d, t, (3)He, and (4)He have been determined at ρ=0.002 to 0.03 nucleons/fm(3) and T=5 to 11 MeV. The experimentally derived equilibrium constants for α particle production are compared with those predicted by a number of astrophysical equations of state. The data provide important new constraints on the model calculations.

12.
Phys Rev Lett ; 108(6): 062702, 2012 Feb 10.
Article in English | MEDLINE | ID: mdl-22401061

ABSTRACT

In-medium binding energies and Mott points for d, t, 3He and α clusters in low-density nuclear matter have been determined at specific combinations of temperature and density in low-density nuclear matter produced in collisions of 47A MeV 40Ar and 64Zn projectiles with 112Sn and 124Sn target nuclei. The experimentally derived values of the in-medium modified binding energies are in good agreement with recent theoretical predictions based upon the implementation of Pauli blocking effects in a quantum statistical approach.

13.
Minerva Pediatr ; 64(1): 55-7, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22350045

ABSTRACT

Systemic lupus erythematosus (SLE) has been reported to be associated to Wilson's disease, as a complication of treatment with penicillamine. Even though drug-induced lupus erythematosus (DILE) has some features in common with SLE, they are distinct entities. We report the case of a young girl who at the age of five had a diagnosis of Wilson's disease and she started therapy with penicillamine. Eight years after the beginning of therapy, she developed proteinuria, which was considered to be related to penicillamine. Two years later, she developed arthritis, malar rash and laboratory findings suggestive for lupus erythematosus. At the beginning her symptoms, due to the known association between penicillamine and DILE, were thought to be related to this treatment. In this hypothesis, she was referred to the Rheumatology Centre; zinc acetate was substituted for penicillamine and she started naproxen for the treatment of arthritis. Anyway, the subsequent clinical course and laboratory findings led us to a diagnosis of idiopathic SLE. A renal biopsy detected massive mesangiocapillary proliferation with subendothelial deposits (wire loops) and duplication of glomerular basement membrane (active diffuse global proliferative lupus nephritis, class IV G A). To our knowledge, this is the first report of an association between Wilson's disease and SLE.


Subject(s)
Hepatolenticular Degeneration/drug therapy , Lupus Erythematosus, Systemic/chemically induced , Penicillamine/adverse effects , Adolescent , Female , Humans
14.
QJM ; 105(2): 109-13, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22252919

ABSTRACT

Chronic hepatitis B (CHB) is a global health problem affecting more than 350 million people worldwide. Chronic carriage of HBV is related to the age when the infection occurs; the younger the age the higher the chronicity rate. Knowledge of the natural history of CHB is important for the management of the disease. The goal of hepatitis B treatment is to prevent cirrhosis, liver decompensation and hepatocellular carcinoma. In clinical practice, treatment response is determined by the suppression of serum HBV DNA levels. However, current antiviral therapies are usually unable to achieve sustained off-treatment responses and eradicate the infection. Impairment of immune responses including defective innate non-cytolytic antiviral function together with exhausted T cells and the tolerogenic liver environment may all contribute to the poor clinical response. A more comprehensive understanding of the immunological phases of CHB, potential triggers of liver flares and molecular mechanisms underlying viral persistence and immunopathology will help to tailor future therapeutic strategies. A synergistic approach of boosting the immune response of the host by specific immunotherapeutic interventions and effective viral load suppression will be needed to promote sustained viral clearance in chronic infection.


Subject(s)
Hepatitis B virus/immunology , Hepatitis B/immunology , Antiviral Agents/therapeutic use , Chronic Disease , Hepatitis B/drug therapy , Hepatitis B virus/genetics , Humans , Viral Load
15.
Pediatr Med Chir ; 34(5): 234-6, 2012.
Article in Italian | MEDLINE | ID: mdl-23342748

ABSTRACT

We describe a case of nephrotic syndrome (NS) after a 7 months treatment with D-penicillamine in a 14 years old girl with Wilson's disease, with a prompt regression at the discontinuation of the drug. Kidney function, proteinuria in particular, must be always monitored during the chelating therapy, and the drug must be discontinued as soon as signs of renal injury are detected.


Subject(s)
Chelating Agents/adverse effects , Hepatolenticular Degeneration/complications , Nephrotic Syndrome/chemically induced , Penicillamine/adverse effects , Adolescent , Chelating Agents/administration & dosage , Female , Hepatolenticular Degeneration/drug therapy , Humans , Penicillamine/administration & dosage , Time Factors , Treatment Outcome , Zinc Acetate/administration & dosage
16.
Pediatr Med Chir ; 33(5-6): 256-8, 2011.
Article in Italian | MEDLINE | ID: mdl-22428436

ABSTRACT

We describe the case of an 11-year-old obese child with nonalcoholic steatohepatitis and Wilson's disease. Nonalcoholic steatohepatitis, although frequently found in patients with obesity, can also be caused by other etiologies, including Wilson's disease, which must therefore always be ruled out in the obese child.


Subject(s)
Fatty Liver/etiology , Obesity/complications , Child , Humans , Male
17.
Appl Radiat Isot ; 69(2): 369-72, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21075000

ABSTRACT

The light output of neutron detectors based on the plastic scintillator EJ228 is studied as a function of neutron energy using a time tagged (252)Cf source. Calibration of the light output scale is performed by fitting the experimental distribution of Compton scattering events of photons from a (22)Na source with a response function obtained by Gaussian smearing of the predicted line-shape. The light output curve as well as the pulse height resolution for the EJ228 scintillators is very close (within 5%) to those recently reported for NE213 type organic liquid scintillators.

18.
Am J Transplant ; 8(12): 2590-9, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18853954

ABSTRACT

To determine whether polyfunctional CD4+ T-cell responses coupled with CD8+ T-cell responses against human cytomegalovirus (HCMV) are key to the control of HCMV replication we prospectively analyzed 29 liver transplant recipients for CD4+ T-cell responses against soluble HCMV antigen, pp65 and IE1 proteins, CD8+ T-cell responses against pp65 and IE1 proteins and a range of T helper (Th) 1 and Th2 cytokines. Eleven patients (38%) developed HCMV DNAemia at a median of 21 days post-liver transplantation (range 17-31 days). There was a significantly lower frequency and absolute number of total HCMV CD4+ T cells producing IFNgamma, IFNgamma+IL2 and IL2 and pp65-CD8+ T cells producing IFNgamma in patients with DNAemia. The quantities of Th1 and Th2 cytokines present during the first 20 days posttransplant were not predictive of DNAemia. Cut-off levels during the first 20 days posttransplant of 0.1% of lysate stimulated CD4+ T cells producing IL2, and pp65-CD8+ T cells producing IFNgamma above 0.4% had positive and negative predictive values for DNAemia of 54% and 100% and 50% and 92%, respectively. Measuring polyfunctional CD4+ T cells against HCMV early posttransplant may allow targeted intervention to minimize the occurrence and acute and long-term consequences of HCMV replication.


Subject(s)
CD4-Positive T-Lymphocytes/physiology , CD8-Positive T-Lymphocytes/physiology , Cytomegalovirus/physiology , Liver Transplantation/physiology , Phosphoproteins/physiology , Viral Matrix Proteins/physiology , Virus Replication/physiology , Adult , Aged , Antigens, Viral/metabolism , DNA, Viral/blood , Female , Humans , Immediate-Early Proteins/metabolism , Interferon-gamma/metabolism , Interleukin-2/metabolism , Linear Models , Male , Middle Aged , Prospective Studies , ROC Curve
20.
Pediatr Med Chir ; 30(1): 48-50, 2008.
Article in Italian | MEDLINE | ID: mdl-18491680

ABSTRACT

Hepatitis A virus infection is usually asymptomatic in children. Classic symptomatic forms and atypical clinical manifestations are known. We report a paediatric case of hepatitis A with marked cholestasis, treated with steroids, and with an unusual prolonged course.


Subject(s)
Hepatitis A , Adolescent , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/therapeutic use , Cholestasis/etiology , Follow-Up Studies , Hepatitis A/complications , Hepatitis A/diagnosis , Hepatitis A/drug therapy , Humans , Male , Prednisone/administration & dosage , Prednisone/therapeutic use , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...